The global endomyocardial biopsy market size was estimated at USD 321.55 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.80% from 2023 to 2030.The growth of the market is being driven by various factors such as increasing prevalence of cardiovascular diseases, advancements in diagnostic technologies, increasing geriatric population, and growing research and development activities. The sedentary lifestyle by the majority of the population has driven the prevalence of various types of CVDs globally. Physical inactivity, smoking, high blood pressure, and obesity are some of the major factors boosting the CVDs rate. For instance, according to CDC, more than 60% of the adults in the U.S. do not engage in recommended physical activity, whereas around 25% of the adults are not active at all. In addition, it was estimated that around 30.8 million people in the U.S. alone smoke cigarettes, whereas 16 million Americans are anticipated to be living with smoking-related disorders.
The COVID-19 pandemic had a negative impact on the endomyocardial biopsies market. Healthcare resources have been strained, leading to a reduction in non-essential procedures, including heart biopsies. However, the pandemic has highlighted the importance of early detection and treatment of underlying medical conditions. Patients with pre-existing heart conditions may be at higher risk for severe diseases if they contract COVID-19, and healthcare providers may prioritize diagnosing and treating these conditions to reduce the risk of complications. This could potentially increase the demand for endomyocardial biopsies.
Furthermore, increasing number of heart transplants has boosted the demand for EMB procedures. Endomyocardial biopsy remains a valuable diagnostic tool for assessing graft function & detecting rejection in heart transplant patients, and it is likely to continue to be used as part of routine post-transplant. According to the data published by the United Network for Organ Sharing, in 2021 approximately 31,238 transplants have been performed at hospitals across the country in the last 10 years and the number has been significantly increasing.
Based on product, the forceps segment accounted for the largest market share of 71.7% in 2022. Forceps are commonly used to perform Endomyocardial Biopsy (EMB) procedures. The development of new and improved forceps with better grip and precision is driving the demand for forceps in EMB procedures. Moreover, forceps are now available in a range of sizes and shapes to suit the needs of different patients and procedures. Companies such as Argon Medical Devices, Inc., Cordis, among others offer a range of forceps which could be used during the biopsy procedures.
The accessories segment is anticipated to register lucrative growth during the forecast period. Several other accessories that are commonly used in EMB procedures are guidewires, biopsy needles, curve tips, and catheters. The choice of an accessory depends on the specific needs of the procedure and the patient's analysis. Furthermore, advancements in EMB accessories, such as flexible needles, and improved imaging tools, have also contributed to the market growth.
The straight tip segment dominated the market in 2022 and accounted for the largest share of 36.7% of the global revenue. The straight tip is designed to allow precision and accuracy during the procedure. The use of a straight tip minimizes the risk of tissue damage during the biopsy, ensuring that the collected tissue is suitable for accurate diagnosis. The straight tip is commonly used for initial puncture and navigation through the heart, allowing for the collection of a tissue sample. Thus, these factors are expected to further drive the segment growth.
Furthermore, the pre-curved segment is expected to expand at a substantial CAGR during the forecast period. The pre-curved tip provides flexibility during the procedure, reducing the risk of damage to surrounding tissues. These factors are expected to further boost the adoption of pre-curved tips during the forecast period.
In 2022, the hospital segment accounted for the largest market share at 50.4%. Factors such as increasing number of transplants, would further increase the volume of procedures performed in the hospitals, thereby generating additional revenue from diagnostic tests and follow-up care which would further improve the patient outcomes. Furthermore, the rising number of hospitals globally is expected to fuel market growth, as more people will have access to healthcare services.
The Ambulatory Surgery Center (ASC) is anticipated to exhibit a significant CAGR of 6.01% during the forecast period. ASCs are majorly preferred by the patients who prefer a more convenient and cost-effective alternative to hospital-based procedures. In addition, with the continuous advancements in technology, EMB procedures can now be safely and effectively performed in an ASC setting, reducing the need for hospitalization.
The North American region held the largest share of 44.5% in 2022. The region has a well-established healthcare infrastructure and a large patient pool with a high prevalence of cardiovascular diseases, which makes it an attractive market for EMB procedures. In addition, the presence of key market players is also contributing to the growth of the market by investing in R&D, introducing innovative products, and providing advanced training and education to healthcare providers.
Asia Pacific is projected to witness the fastest growth during the forecast period.The growth of the market is attributed to factors such as increasing awareness about heart diseases and the need for early diagnosis & treatment. Furthermore, improving healthcare infrastructure in the region has boosted the availability of endomyocardial biopsy services.
The endomyocardial biopsy market is consolidated and has major key market players such as Argon Medica Devices, Inc., Cordis, Mermaid Medical, Terumo Corporation, Scholten Surgical Instruments, Inc., Changzhou Lookmed Medical Instrument Co., Ltd., and Fehling Instruments. These players focus on growth strategies, such as new product launches, collaborations, partnerships, expansion, and mergers & acquisitions.
For instance, in May 2022, Terumo Corporation (Terumo India) entered into a partnership agreement with Argon Medical to offer advanced medical solutions, which would provide support from diagnosis to treatment to patients.Some of the prominent players in the global endomyocardial biopsy market include:
Argon Medica Devices, Inc.
Cordis
Mermaid Medical
Terum Corporation
Scholten Surgical Instruments, Inc.
Changzhou Lookmed Medical Instrument Co., Ltd.
Fehling Instruments
Report Attribute |
Details |
Market size value in 2023 |
USD 342.65 million |
Revenue forecast in 2030 |
USD 543.00 million |
Growth Rate |
CAGR of 6.8% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, tip, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Argon Medica Devices, Inc.; Cordis; Mermaid Medical; Terum Corporation; Scholten Surgical Instruments, Inc.; Changzhou Lookmed Medical Instrument Co., Ltd.; Fehling Instruments |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global endomyocardial biopsy market report on the basis of product, tip, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Forceps
Accessories
Tip Outlook (Revenue, USD Million, 2018 - 2030)
Maxi-curved
Straight
Pre-curved
Others
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Ambulatory Surgical Centers
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global endomyocardial biopsy market size was estimated at USD 321.5 million in 2022 and is expected to reach USD 342.7 million in 2023.
b. The global endomyocardial biopsy market is expected to grow at a compound annual growth rate of 6.8% from 2023 to 2030 to reach USD 543.0 million by 2030.
b. North America dominated the endomyocardial biopsy market with a share of 44.5% in 2022. This is attributable to well-developed healthcare facilities and the local presence of many large medical device companies.
b. Some key players operating in the endomyocardial biopsy market include Argon Medica Devices, Inc., Cordis, Mermaid Medical, Terumo Corporation, Scholten Surgical Instruments, Inc., Changzhou Lookmed Medical Instrument Co., Ltd., and Fehling Instruments
b. Key factors that are driving the endomyocardial biopsy market growth include an increase in the incidence of cardiac diseases, the introduction of technologically advanced products, and favourable reimbursement scenario for cardiac interventional procedures.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."